ANI Pharmaceuticals Inc (ANIP):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9770)
◆英語タイトル:ANI Pharmaceuticals Inc (ANIP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9770
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:69
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
ANI Pharmaceuticals Inc (ANI) formerly BioSante Pharmaceuticals Inc, is a specialty pharmaceutical company that develops, manufactures and markets pharmaceuticals. The company’s product portfolio encompasses generic and branded tablets indicated for ulcerative colitis; osteoarthritis; rheumatoid arthritis; primary hypercholesterolemia; severe hypertriglyceridemia; arrhythmia; obsessive-compulsive disorder; social anxiety disorder; ulcerative proctitis; ulcerative proctosigmoiditis; bipolar disorder; glaucoma; metastatic prostate cancer; diarrhea; and pain. It caters to markets including oncolytics; complex formulations, hormones and steroids; and controlled substances. ANI also undertakes contract manufacturing of coated and non-coated capsules; oral dosage forms; liquid solution; topical liquids; suspension forms; and tablets. The company sells its products to wholesalers, group purchasing organizations, mail order houses in the US, and pharmacy retail outlets. ANI is headquartered in Baudette, Minnesota, the US.

ANI Pharmaceuticals Inc (ANIP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 13
ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 15
ANI Pharma Acquires Generic ANDA Product Portfolio from IDT Australia for USD2.7 Million 16
ANI Pharma Acquires Four NDA’s from AstraZeneca 17
ANI Pharma Acquires Inderal XL from Cranford Pharma for USD20 Million 18
ANI Pharma Acquires InnoPran XL from Holmdel Pharma for USD31 Million 19
ANI Pharma Acquires Inderal LA Assets from Cranford Pharma 20
ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 21
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma 22
ANI Pharma Acquires ANDA from Teva Pharma 23
ANI Pharma Acquires Vancocin Capsules and Vancomycin Assets from Shire for USD11 Million 24
ANI Pharma Acquires Lithobid from Noven Therapeutics for USD12 Million 25
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 26
Partnerships 27
ANI Pharma Enters into Distribution Agreement with Aspen 27
ANI Pharma Enters into Agreement with H2-Pharma 28
ANI Pharma Enters into Agreement with IDT Australia 29
ANI Pharma Extends Co-Development Agreement With Sterling Pharma 30
ANI Pharma Enters Into Development Agreement With Sterling Pharma 31
Ani Pharma Enters Into Co-Development Agreement With Sofgen Pharma For Oral Soft Gel Prescription Product 32
Merger 33
BioSante Pharma And Ani Pharma Complete Merger 33
Licensing Agreements 35
ANI Pharma Enters into Licensing Agreement with Dexcel Pharma 35
Ani Pharma Enters Into Licensing Agreement With Sofgen Pharma For Oral Soft Gel Product 36
Equity Offering 37
WellSpring Pharma Services Invests USD3 Million in IDT Australia 37
ANI Pharma Completes Public Offering Of Shares For US$50 Million 38
Debt Offering 39
ANI Pharma Raises USD143.8 Million in Public Offering of 3% Notes Due 2019 39
ANI Pharma Raises USD287.5 Million in Public Offering of 2.125% Notes Due 2023 41
Acquisition 42
ANI Pharma Acquires WellSpring Pharma from Sentinel Capital for USD18 Million 42
ANI Pharmaceuticals Inc – Key Competitors 43
ANI Pharmaceuticals Inc – Key Employees 44
ANI Pharmaceuticals Inc – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Recent Developments 46
Financial Announcements 46
Aug 07, 2018: ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance 46
May 08, 2018: ANI Pharmaceuticals Reports First Quarter 2018 Results and Reaffirms Guidance 51
Feb 27, 2018: ANI Pharmaceuticals Reports Record Full Year Results, Reports Fourth Quarter 2017 Results, and Provides 2018 Guidance 54
Nov 02, 2017: ANI Pharmaceuticals Reports Record Third Quarter and Year-To-Date 2017 Results and Narrows Full Year Guidance 58
Aug 03, 2017: ANI Pharmaceuticals Reports Record Second Quarter and Year-To-Date 2017 Results and Reaffirms Guidance 61
May 04, 2017: ANI Pharmaceuticals Reports First Quarter Results and Year-To-Date 2017 Highlights and Reaffirms Guidance 63
Mar 02, 2017: ANI Pharmaceuticals Reports Full Year 2016 Results and Fourth Quarter Results and Provides 2017 Guidance 65
Corporate Communications 68
Jun 05, 2018: ANI Pharmaceuticals Appoints Three New Board of Directors 68
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69

List of Tables
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ANI Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 13
ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 15
ANI Pharma Acquires Generic ANDA Product Portfolio from IDT Australia for USD2.7 Million 16
ANI Pharma Acquires Four NDA’s from AstraZeneca 17
ANI Pharma Acquires Inderal XL from Cranford Pharma for USD20 Million 18
ANI Pharma Acquires InnoPran XL from Holmdel Pharma for USD31 Million 19
ANI Pharma Acquires Inderal LA Assets from Cranford Pharma 20
ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 21
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma 22
ANI Pharma Acquires ANDA from Teva Pharma 23
ANI Pharma Acquires Vancocin Capsules and Vancomycin Assets from Shire for USD11 Million 24
ANI Pharma Acquires Lithobid from Noven Therapeutics for USD12 Million 25
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 26
ANI Pharma Enters into Distribution Agreement with Aspen 27
ANI Pharma Enters into Agreement with H2-Pharma 28
ANI Pharma Enters into Agreement with IDT Australia 29
ANI Pharma Extends Co-Development Agreement With Sterling Pharma 30
ANI Pharma Enters Into Development Agreement With Sterling Pharma 31
Ani Pharma Enters Into Co-Development Agreement With Sofgen Pharma For Oral Soft Gel Prescription Product 32
BioSante Pharma And Ani Pharma Complete Merger 33
ANI Pharma Enters into Licensing Agreement with Dexcel Pharma 35
Ani Pharma Enters Into Licensing Agreement With Sofgen Pharma For Oral Soft Gel Product 36
WellSpring Pharma Services Invests USD3 Million in IDT Australia 37
ANI Pharma Completes Public Offering Of Shares For US$50 Million 38
ANI Pharma Raises USD143.8 Million in Public Offering of 3% Notes Due 2019 39
ANI Pharma Raises USD287.5 Million in Public Offering of 2.125% Notes Due 2023 41
ANI Pharma Acquires WellSpring Pharma from Sentinel Capital for USD18 Million 42
ANI Pharmaceuticals Inc, Key Competitors 43
ANI Pharmaceuticals Inc, Key Employees 44
ANI Pharmaceuticals Inc, Other Locations 45
ANI Pharmaceuticals Inc, Subsidiaries 45

List of Figures
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ANI Pharmaceuticals Inc (ANIP):製薬・医療:M&Aディール及び事業提携情報(ANI Pharmaceuticals Inc (ANIP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆